Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 8/20 | 0.38 |
| ▸ | ATR | Q13535 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655465 | 0.87 | PIK3CD (0.43) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL16655699 | 0.80 | PIK3CD (0.42) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20533284 | 0.70 | EGFR (0.52) | EGFRBTKCSF1R | |
| SCHEMBL16655686 | 0.69 | PIK3CD (0.41) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3123123 | 0.67 | EGFR (0.47) | EGFRBTK | |
| SCHEMBL22710619 | 0.66 | BTK (0.64) | BTK | |
| SCHEMBL30387689 | 0.65 | PIK3CD (0.65) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL21044835 | 0.65 | BTK (0.73) | EGFRBTK | |
| SCHEMBL3607743 | 0.65 | RET (0.52) | EGFRPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3117175 | 0.64 | HTR6 (0.47) | EGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | EGFR 828/4885PIK3CD 2/4885PIK3CA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.